Concert Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Show Pharmaceuticals is a clinical stage biotechnology organization committed to making new prescriptions through a clever logical methodology using the normally happening component deuterium. Show applies its imaginative accuracy deuterium science stage to change explicit properties of approved drug particles, yielding a rich pipeline of new substance elements (NCEs). Show use many years of drug insight to make novel medication up-and-comers with potential for top tier viability and wellbeing, while extraordinarily lessening R&D hazard, time and cost.
Concert Pharmaceuticals has raised $66.4M across 1 funding round on record, the most recent a Post-IPO Equity of $66.4M announced in Jun 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Concert Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2022.
Concert Pharmaceuticals Funding Rounds
Concert Pharmaceuticals Founders and Leadership Team
Contact details for the Concert Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Concert Pharmaceuticals Funding Compared to Other Biotechnology Startups
Concert Pharmaceuticals' latest round of $66.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Concert Pharmaceuticals in Biotechnology and Lexington
Companies Similar to Concert Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Concert Pharmaceuticals Funding FAQs
What does Concert Pharmaceuticals do?
Show Pharmaceuticals is a clinical stage biotechnology organization committed to making new prescriptions through a clever logical methodology using the normally happening component deuterium. Show applies its imaginative accuracy deuterium science stage to change explicit properties of approved drug particles, yielding a rich pipeline of new substance elements (NCEs). Show use many years of drug insight to make novel medication up-and-comers with potential for top tier viability and wellbeing, while extraordinarily lessening R&D hazard, time and cost.
How much funding has Concert Pharmaceuticals raised?
Concert Pharmaceuticals has raised $66.4M across 1 round on record. The most recent is a Post-IPO Equity of $66.4M announced in Jun 2022.
When did Concert Pharmaceuticals last raise funding?
Concert Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $66.4M, announced in Jun 2022.
Who is the CEO of Concert Pharmaceuticals?
Roger Tung is listed as CEO at Concert Pharmaceuticals.
Where is Concert Pharmaceuticals headquartered?
Concert Pharmaceuticals is based in Lexington, Massachusetts, United States.
How many employees does Concert Pharmaceuticals have?
Concert Pharmaceuticals is in the 51-100 employee band.
How does Concert Pharmaceuticals' funding compare to other Biotechnology startups?
Concert Pharmaceuticals' latest round of $66.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Concert Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Concert Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.